Article
Gilteritinib response in acute myeloid leukemia harboring a rare FLT3 juxtamembrane domain mutation with subsequent clonal evolution.
Annals of hematology - 9 May 2026
Nakao Fumihiko, Shima Takahiro, Takigawa Ken, Semba Yuichiro, Jinnouchi Fumiaki, Yamauchi Takuji, Odawara Jun, Kikushige Yoshikane, Mori Yasuo, Kato Koji, Maeda Takahiro, Akashi Koichi
Abstract excerpt
Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are among the most clinically relevant molecular abnormalities in acute myeloid leukemia (AML); however, the therapeutic significance of rare non-canonical FLT3 mutations involving the juxtamembrane domain (JMD) remains poorly defined. We re...
Topics
- Humans
- fms-Like Tyrosine Kinase 3
- Female
- Aniline Compounds
- Pyrazines
- Adult
- Leukemia, Myeloid, Acute
- Clonal Evolution
- Mutation, Missense
- Hematopoietic Stem Cell Transplantation
- Protein Domains
- Mutation